구조모아 (StructureMoa)항암 chemical structure spider web
방문Minsk Scientific-Practical Center for SurgeryTransplantationHematology
CD19+22 CAR-T cells(Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology)은 CD19 표적 세포·유전자 치료로, Acute Lymphobkastic Leukemia; B Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 1% (ClinicalTrials.gov NCT03287817). 차별점: novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high respons.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
CD19
Acute Lymphobkastic Leukemia; B Cell Lymphoma
Recruiting
2026-07-18
Data Confidence · Medium
Development Signal · Emerging
CAR T cells in children, adolescents and young adults with B-ALL:
lentiviral cotransduction with vectors encoding our previously described fast-off rate CD1
humanized mice, led to development of a novel bicistronic CD19
novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high respons
targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen
cytokine release syndrome (CRS); only 2 (10%) were grade > 3
CD19 and CD22 (CAR19-22), which was well tolerated and associated with high
escape observed after single antigen targeting therapy
구조화 데이터
mouse, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Minsk Scientific-Practical Center for SurgeryTransplantationHematology
CD19+22 CAR-T cells(Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology)은 CD19 표적 세포·유전자 치료로, Acute Lymphobkastic Leukemia; B Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. 선택한 코호트에서 보고된 효능: ORR 1% (ClinicalTrials.gov NCT03287817). 차별점: novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high respons.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
CD19
Acute Lymphobkastic Leukemia; B Cell Lymphoma
Recruiting
2026-07-18
Data Confidence · Medium
Development Signal · Emerging
CAR T cells in children, adolescents and young adults with B-ALL:
lentiviral cotransduction with vectors encoding our previously described fast-off rate CD1
humanized mice, led to development of a novel bicistronic CD19
novel autologous bispecific CAR targeting CD19 and CD22 (CAR19-22), which was well tolerated and associated with high respons
targeting chimeric antigen receptor (CAR) T cells have emerged as a strategy to mitigate antigen escape observed after single antigen
cytokine release syndrome (CRS); only 2 (10%) were grade > 3
CD19 and CD22 (CAR19-22), which was well tolerated and associated with high
escape observed after single antigen targeting therapy
구조화 데이터
mouse, mouse
pharmacokinetic
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.